COZADD BRUCE C sold $1.4M of JAZZ
COZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $230.33 ($1.38M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director's $1.38M sale may prompt short‑term price pressure, but the remaining large holding tempers the signal.
Market read
Insider sales are closely watched; this filing provides fresh data for traders assessing short‑term risk.
What to watch
The director still holds a sizable stake (over 300k shares), indicating continued confidence.
Background
Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.
Ticker impact
Director Cozadd Bruce C sold 6,000 shares for $1.38M via a 10b5‑1 plan, reducing his stake to 345,875 shares.
likely modest pressure as the market prices in the insider sell
Form 4 is a primary source; a $1.4M sale by a director is material enough to move sentiment, though the amount is modest relative to market cap.
Market effects
May signal slight concern for the pharma sector if other insiders follow suit.
Limited to U.S. markets where Jazz trades.
Minimal global impact; primarily a company‑specific event.
Counterpoint
The sale could be routine under a 10b5‑1 plan and not indicate any negative fundamentals.
Key entities
- companyJazz Pharmaceuticals plc
U.S.-listed pharmaceutical company (ticker JAZZ).
- personCozadd Bruce C
Director of Jazz Pharmaceuticals executing a 10b5‑1 sale.
